Virbac S.A. stock (FR0000031577): Animal health group reports solid 2024 results and updates outlook

Virbac S.A. has published full-year 2024 results and an outlook for 2025, highlighting growth in companion animal products and continued investment in innovation, while its Euronext Paris–listed shares remain a niche way for U.S. investors to access the global animal health market.

Virbac S.A. has recently drawn investor attention after reporting its full-year 2024 results and updating its 2025 outlook, underlining continued growth in companion animal health and steady performance in livestock, according to a press release on the company’s investor relations site dated March 18, 2025 (Virbac investor relations as of 03/18/2025). The French animal health specialist, whose shares trade on Euronext Paris under the ticker VIRP, remains a comparatively small but relevant player for U.S. investors looking beyond the large U.S.-listed animal health groups.

As of: 05/20/2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Virbac
• Sector/industry: Animal health / pharmaceuticals
• Headquarters/country: Carros, France
• Core markets: Europe, North America, Latin America, Asia-Pacific
• Key revenue drivers: Veterinary medicines, vaccines, and pet health products
• Home exchange/listing venue: Euronext Paris (ticker: VIRP)
• Trading currency: EUR

Virbac S.A.: core business model

Virbac S.A. focuses exclusively on animal health, developing, manufacturing, and marketing medicines, vaccines, diagnostics, and nutrition products for both companion animals and livestock. The group positions itself as a pure-play alternative to diversified pharmaceutical companies, with a portfolio that spans prescription treatments, vaccines, parasiticides, dermatology solutions, and nutritional supplements for animals, according to its corporate profile and latest annual report published in March 2025 for the 2024 financial year (Virbac regulated information as of 03/18/2025).

The company’s operations are structured around two main segments: companion animals, which include dogs, cats, and other pets, and food-producing animals such as cattle, swine, and poultry. Over the past years, Virbac has gradually shifted its mix toward companion animals, reflecting global trends of increasing pet ownership and rising spending on veterinary care. In 2024, companion animals accounted for a majority of revenue, while livestock maintained a significant contribution in certain regions, particularly Latin America and parts of Asia, based on the 2024 annual report released in March 2025 for the 2024 financial year (Virbac annual report as of 03/18/2025).

Virbac’s business model relies on close relationships with veterinarians, clinics, and distributors, who act as key decision makers for product adoption. The company invests in targeted R&D to expand its pipeline of vaccines, antiparasitics, dermatology therapies, and specialty treatments for chronic conditions in animals. It also operates manufacturing sites and development centers across Europe, the Americas, and Asia, which support regional supply and help adapt formulations to local regulatory and market requirements.

Main revenue and product drivers for Virbac S.A.

Virbac’s revenue is driven by a broad range of veterinary medicinal products and vaccines, with a growing emphasis on companion animal lines. In 2024, the company reported year-on-year revenue growth supported by demand in parasiticides, dermatology products, and specialty treatments for companion animals, according to the 2024 results press release dated March 18, 2025 (Virbac press release as of 03/18/2025). The company highlighted particularly solid dynamics in Europe and North America, where pet ownership remains high and veterinary services are well established.

Livestock products, including vaccines and treatments for cattle, swine, and poultry, remain an important contributor, especially in emerging markets. In 2024, Virbac noted mixed trends in this segment, with some pressure in markets facing economic or regulatory headwinds but more resilient demand in others, according to the same 2024 results communication from March 18, 2025 (Virbac press release as of 03/18/2025). The flexibility of Virbac’s production network helps it respond to changing conditions, including disease outbreaks or shifts in local regulations affecting food-producing animals.

Beyond traditional pharmaceutical products, Virbac also generates revenue from nutrition and dietetic products, such as therapeutic pet foods and supplements designed to support specific health conditions. While this area is smaller than core pharmaceuticals, it provides cross-selling opportunities through veterinary clinics and reinforces the company’s positioning as a comprehensive partner for animal health. Over time, management has pointed to innovation in differentiated formulations and convenient administration methods as a way to maintain pricing power and strengthen relationships with veterinarians.

Industry trends and competitive position

The global animal health market has benefited from long-term tailwinds, including rising pet ownership, advances in veterinary medicine, and increasing awareness of zoonotic diseases that can pass between animals and humans. Market research providers such as IQVIA and sector analysts have pointed to steady mid-single-digit growth for the animal health industry in recent years, with companion animals generally growing faster than livestock. Within this context, Virbac competes with significantly larger peers, including U.S.-listed groups, while aiming to differentiate through breadth of portfolio and focus on under-served segments.

Virbac’s positioning is that of a mid-sized specialist with a presence across many geographies but a more concentrated focus than diversified pharmaceutical companies. Its scale allows it to maintain a meaningful R&D program and global footprint, yet it operates with fewer resources than several leading global players. That reality shapes its strategy, which emphasizes targeted innovation in therapeutic niches, partnerships in certain markets, and disciplined capital allocation. The company has at times pursued bolt-on acquisitions or product licensing agreements to complement its portfolio, while also investing in manufacturing upgrades and supply-chain resilience.

Competitive pressures are most visible in widely used product categories such as parasiticides, vaccines, and antibiotics, where larger competitors can leverage scale in marketing and production. At the same time, regulatory scrutiny on antibiotics in food-producing animals and evolving rules on veterinary medicines in regions like Europe and North America create both challenges and opportunities. For a company like Virbac, the ability to adapt quickly to changing regulations and to shift its mix toward higher-value, differentiated products is a core part of its competitive strategy.

Why Virbac S.A. matters for US investors

Although Virbac’s shares are listed on Euronext Paris rather than a U.S. exchange, the company has a meaningful presence in North America and competes in the same market segments as several U.S.-listed animal health groups. For U.S.-based investors, the stock can represent an indirect way to gain exposure to structural trends in pet healthcare and veterinary services, complementing domestic holdings in similar businesses. The company’s North American operations deliver a notable portion of its revenue, supported by demand for companion animal products in the United States and Canada, according to the 2024 annual report published in March 2025 for the 2024 financial year (Virbac annual report as of 03/18/2025).

Currency exposure is an important consideration for U.S. investors assessing Virbac. The stock trades in euros, and the company reports its results in euros, so investment outcomes are influenced both by the performance of the underlying business and by EUR/USD exchange-rate movements. For investors looking to diversify beyond U.S.-dollar assets and broaden their exposure within the animal health sector, this foreign-currency aspect may be either a potential diversification benefit or an additional source of volatility, depending on individual circumstances and risk tolerance.

From a portfolio-construction perspective, Virbac occupies a niche between large-cap global animal health leaders and smaller regional players. Its scale, geographic footprint, and product breadth provide exposure to global veterinary trends, while its European listing and mid-cap profile differentiate it from many U.S. benchmarks. For U.S. investors monitoring the sector, Virbac’s earnings releases, guidance updates, and regional performance metrics can also offer insight into broader trends in veterinary practices, pet healthcare spending, and livestock health dynamics across multiple continents.

Conclusion

Virbac S.A. remains a focused player in the global animal health market, with 2024 results highlighting ongoing growth in companion animal products and a diversified geographic footprint, according to the company’s March 18, 2025 earnings communications (Virbac press release as of 03/18/2025). For U.S. investors, the stock offers exposure to structural trends in pet care and livestock health through a euro-denominated, Euronext-listed name that operates alongside the larger U.S.-listed animal health groups. As with any equity investment, key factors to monitor include the company’s execution on its product pipeline, its ability to navigate regulatory and competitive pressures, and the impact of currency movements on reported results and valuation metrics.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.